COVID-19 research briefs: case series shows early promise for remdesivir

Daily POEMs

Published: 2020-05-05 © 2020 John Wiley & Sons, Inc.

Printer Friendly

Clinical question
Can remdesivir improve outcomes in patients with COVID-19?

Bottom line
This uncontrolled case series of 53 patients with COVID-19 shows early promise for remdesvir, but further evidence from randomized controlled trials is needed. (LOE = 4)

Reference
Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe COVID-19. [published online ahead of print, 2020 Apr 10] N Engl J Med 2020;NEJMoa2007016. doi:10.1056/NEJMoa2007016.

Study design: Case series

Setting: Inpatient (ICU only)

Synopsis
Research Brief #11: This uncontrolled case series reported the outcomes for 53 patients with COVID-19 who were treated with remdesivir; 40 of them received the full course of therapy (200 mg on day 1, 100 mg once daily on days 2 through 10). The median age of the patients was 64 years and the median follow-up duration was 18 days. Of the 34 patients who received invasive ventilation, 6 died, 9 were still on a ventilator, 3 had improved to noninvasive ventilation, and 16 were on room air or had been discharged. Of the 7 on noninvasive ventilation, 1 died, 1 was on invasive ventilation, and 5 had been discharged. Of the 12 on low-flow oxygen or room air, all had been discharged. Although the outcomes compare favorably with other published series, randomized trials to provide suitable evidence that this drug is effective are ongoing.

Mark H. Ebell, MD, MS
Professor
University of Georgia
Athens, GA

Copyright © 2020 John Wiley & Sons, Inc.